Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium : 2020 update
To guide health care professionals in Belgium in selecting the appropriate antiepileptic drugs (AEDs) for their epilepsy patients, a group of Belgian epilepsy experts developed recommendations for AED treatment in adults and children (initial recommendations in 2008, updated in 2012). As new drugs have become available, others have been withdrawn, new indications have been approved and recommendations for pregnant women have changed, a new update was pertinent. A group of Belgian epilepsy experts (partly overlapping with the group in charge of the 2008/2012 recommendations) evaluated the most... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journalarticle |
Erscheinungsdatum: | 2020 |
Schlagwörter: | Medicine and Health Sciences / DRUG-RESISTANT EPILEPSY / UNCONTROLLED FOCAL EPILEPSY / ACADEMY-OF-NEUROLOGY / ANTIEPILEPTIC DRUGS / TASK-FORCE / PHARMACODYNAMIC / INTERACTIONS / ADJUNCTIVE TREATMENTS / INTERNATIONAL LEAGUE / INITIAL / MONOTHERAPY / QSS SUBCOMMITTEES / Epilepsy / Seizures / Recommendations / Add-on therapy |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26993185 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://biblio.ugent.be/publication/8703384 |
To guide health care professionals in Belgium in selecting the appropriate antiepileptic drugs (AEDs) for their epilepsy patients, a group of Belgian epilepsy experts developed recommendations for AED treatment in adults and children (initial recommendations in 2008, updated in 2012). As new drugs have become available, others have been withdrawn, new indications have been approved and recommendations for pregnant women have changed, a new update was pertinent. A group of Belgian epilepsy experts (partly overlapping with the group in charge of the 2008/2012 recommendations) evaluated the most recent international guidelines and relevant literature for their applicability to the Belgian situation (registration status, reimbursement, clinical practice) and updated the recommendations for initial monotherapy in adults and children and add-on treatment in adults. Recommendations for add-on treatment in children were also included (not covered in the 2008/2012 publications). Like the 2008/2012 publications, the current update also covers other important aspects related to the management of epilepsy, including the importance of early referral in drug-resistant epilepsy, pharmacokinetic properties and tolerability of AEDs, comorbidities, specific considerations in elderly and pregnant patients, generic substitution and the rapidly evolving field of precision medicine.